Title of Meeting

**DISCLOSURES**

Date of Meeting

Venue, City, State

**Disclosure Policy and Disclosures**
As required by the Accreditation Council for Continuing Medical Education (ACCME) and in accordance with the American College of Allergy, Asthma and Immunology (ACAAI) policy, all educational planners, presenters, instructors, moderators, authors, reviewer, and other individuals in a position to control or influence the content of an activity must disclose ALL financial relationships with any ineligible company. The ACCME defines an “ineligible company” (formerly commercial interest) as a company whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients. (*Examples of ineligible companies include: Advertising, marketing, or communication firms whose clients are ineligible companies; bio-medical startups that have begun a governmental regulatory approval process; compounding pharmacies that manufacture proprietary compounds; device manufacturers or distributors; diagnostic labs that sell proprietary products; growers, distributors, manufacturers or sellers of medical foods and dietary supplements; manufacturers of health-related wearable products; pharmaceutical companies or distributors; pharmacy benefit managers; reagent manufacturers or sellers*). For more information, visit [www.accme.org](http://www.accme.org).

Disclosure in no way implies that the information presented is biased or of lesser quality. It is incumbent upon course participants to be aware of these factors in interpreting the program contents and evaluating recommendations. Moreover, expressed views do not necessarily reflect the opinions of the ACAAI.

**All identified conflicts of interest have been mitigated.**

James Valentine, MD (SAMPLE)
Consultant: Astra Zeneca, Regeneron, Novartis
Speaker: DBV Tech, Aimmune

 **The following have no relevant financial relationships to disclose:**Ruth Johnson, MD (SAMPLE)
Jonathan August, MD